Cargando…

Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience

BACKGROUND: The number of cases of novel coronavirus disease 2019 (COVID-19) in Japan have risen since the first case was reported on January 24, 2020, and 6225 infections have been reported as of June 30, 2020. On April 8, 2020, our hospital began screening patients via pre-admission reverse transc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogami, Yuya, Kobayashi, Yusuke, Tsuji, Kosuke, Yokota, Megumi, Nishio, Hiroshi, Nakamura, Masaru, Yamagami, Wataru, Morisada, Tohru, Tominaga, Eiichiro, Banno, Kouji, Aoki, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485922/
https://www.ncbi.nlm.nih.gov/pubmed/32917254
http://dx.doi.org/10.1186/s13048-020-00711-x
_version_ 1783581245544857600
author Nogami, Yuya
Kobayashi, Yusuke
Tsuji, Kosuke
Yokota, Megumi
Nishio, Hiroshi
Nakamura, Masaru
Yamagami, Wataru
Morisada, Tohru
Tominaga, Eiichiro
Banno, Kouji
Aoki, Daisuke
author_facet Nogami, Yuya
Kobayashi, Yusuke
Tsuji, Kosuke
Yokota, Megumi
Nishio, Hiroshi
Nakamura, Masaru
Yamagami, Wataru
Morisada, Tohru
Tominaga, Eiichiro
Banno, Kouji
Aoki, Daisuke
author_sort Nogami, Yuya
collection PubMed
description BACKGROUND: The number of cases of novel coronavirus disease 2019 (COVID-19) in Japan have risen since the first case was reported on January 24, 2020, and 6225 infections have been reported as of June 30, 2020. On April 8, 2020, our hospital began screening patients via pre-admission reverse transcriptase-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and chest computed tomography (CT). Although no patients exhibited apparent pneumonia, treatment delay or changes in treatment plans were required for a few patients based on the results of screening tests. During an emerging infectious disease pandemic, the likelihood of being infected, as well as the disease itself, affects clinical decision making in several ways. We summarized and presented our experience. CASE PRESENTATION: After the introduction of pre-admission screening, RT-PCR and CT were performed in 200 and 76 patients, respectively, as of June 30, 2020. The treatment of five patients, including two patients with cervical cancer, two patients with ovarian tumors, and one patient with ovarian cancer, was affected by the results. Two asymptomatic RT-PCR-positive patients did not develop COVID-19, but their treatment was delayed until the confirmation of negative results. The other three patients were RT-PCR-negative, but abnormal CT findings suggested the possibility of COVID-19, which delayed treatment. The patients receiving first-line preoperative chemotherapy for ovarian cancer had clinically evident exacerbations because of the treatment delay. CONCLUSION: During the epidemic phase of an emerging infectious disease, we found that COVID-19 has several other effects besides its incidence. The postponing treatment was the most common, therefore, treatment of ovarian tumors and ovarian cancer was considered to be the most likely to be affected among gynecological diseases. Protocols that allow for easy over-diagnosis can be disadvantageous, mainly because of treatment delays, and therefore, the protocols must be developed in light of the local infection situation.
format Online
Article
Text
id pubmed-7485922
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74859222020-09-14 Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience Nogami, Yuya Kobayashi, Yusuke Tsuji, Kosuke Yokota, Megumi Nishio, Hiroshi Nakamura, Masaru Yamagami, Wataru Morisada, Tohru Tominaga, Eiichiro Banno, Kouji Aoki, Daisuke J Ovarian Res Case Report BACKGROUND: The number of cases of novel coronavirus disease 2019 (COVID-19) in Japan have risen since the first case was reported on January 24, 2020, and 6225 infections have been reported as of June 30, 2020. On April 8, 2020, our hospital began screening patients via pre-admission reverse transcriptase-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and chest computed tomography (CT). Although no patients exhibited apparent pneumonia, treatment delay or changes in treatment plans were required for a few patients based on the results of screening tests. During an emerging infectious disease pandemic, the likelihood of being infected, as well as the disease itself, affects clinical decision making in several ways. We summarized and presented our experience. CASE PRESENTATION: After the introduction of pre-admission screening, RT-PCR and CT were performed in 200 and 76 patients, respectively, as of June 30, 2020. The treatment of five patients, including two patients with cervical cancer, two patients with ovarian tumors, and one patient with ovarian cancer, was affected by the results. Two asymptomatic RT-PCR-positive patients did not develop COVID-19, but their treatment was delayed until the confirmation of negative results. The other three patients were RT-PCR-negative, but abnormal CT findings suggested the possibility of COVID-19, which delayed treatment. The patients receiving first-line preoperative chemotherapy for ovarian cancer had clinically evident exacerbations because of the treatment delay. CONCLUSION: During the epidemic phase of an emerging infectious disease, we found that COVID-19 has several other effects besides its incidence. The postponing treatment was the most common, therefore, treatment of ovarian tumors and ovarian cancer was considered to be the most likely to be affected among gynecological diseases. Protocols that allow for easy over-diagnosis can be disadvantageous, mainly because of treatment delays, and therefore, the protocols must be developed in light of the local infection situation. BioMed Central 2020-09-11 /pmc/articles/PMC7485922/ /pubmed/32917254 http://dx.doi.org/10.1186/s13048-020-00711-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Nogami, Yuya
Kobayashi, Yusuke
Tsuji, Kosuke
Yokota, Megumi
Nishio, Hiroshi
Nakamura, Masaru
Yamagami, Wataru
Morisada, Tohru
Tominaga, Eiichiro
Banno, Kouji
Aoki, Daisuke
Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience
title Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience
title_full Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience
title_fullStr Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience
title_full_unstemmed Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience
title_short Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience
title_sort impact of the covid-19 epidemic at a high-volume facility in gynecological oncology in tokyo, japan: a single-center experience
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485922/
https://www.ncbi.nlm.nih.gov/pubmed/32917254
http://dx.doi.org/10.1186/s13048-020-00711-x
work_keys_str_mv AT nogamiyuya impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT kobayashiyusuke impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT tsujikosuke impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT yokotamegumi impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT nishiohiroshi impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT nakamuramasaru impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT yamagamiwataru impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT morisadatohru impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT tominagaeiichiro impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT bannokouji impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience
AT aokidaisuke impactofthecovid19epidemicatahighvolumefacilityingynecologicaloncologyintokyojapanasinglecenterexperience